⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for oprozomib

Every month we try and update this database with for oprozomib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple MyelomaNCT01832727
Multiple Myelom...
Oprozomib
Dexamethasone
18 Years - Amgen
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid TumorsNCT01129349
Solid Tumors
Oprozomib
18 Years - Amgen
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaNCT01881789
Multiple Myelom...
Oprozomib
Lenalidomide
Dexamethasone
Cyclophosphamid...
18 Years - Amgen
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaNCT02227914
Advanced Hepato...
Oprozomib
Sorafenib
18 Years - Amgen
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular CarcinomaNCT02227914
Advanced Hepato...
Oprozomib
Sorafenib
18 Years - Amgen
Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid TumorsNCT01129349
Solid Tumors
Oprozomib
18 Years - Amgen
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple MyelomaNCT01881789
Multiple Myelom...
Oprozomib
Lenalidomide
Dexamethasone
Cyclophosphamid...
18 Years - Amgen
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced MalignanciesNCT02244112
Advanced Non-Ce...
Oprozomib
Midazolam
18 Years - Amgen
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic MalignanciesNCT01416428
Multiple Myelom...
Waldenstrom Mac...
oprozomib
18 Years - Amgen
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: